NCT00388193

Rituximab Combined With Chemotherapy in Burkitt's Lymphoma

Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: PETHEMA Foundation · Academic / Other
• Sex: All
• Age: 15 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical trial is to prove the efficacy of the following new regimen treatment: * Administration of anti-CD20 (Rituximab) combined with chemotherapy. * Combined treatment with high doses of methotrexate and high doses of cytarabine with conventional cytostatics (block C) * Prophylactic administration of G-CSF after all chemotherapy cycles * local irradiation after 6 cycle if CNS was affected or if there are residual tumour

Detailed description

Clinical Trial with a pharmaceutical speciality in new conditions to use.

Conditions

• Acute Lymphoblastic Leukemia
• Burkitt's Lymphoma

Interventions

Type	Name	Description
DRUG	RITUXIMAB	375 mg/m2/d day 1

Timeline

• Start date: 2006-08-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2006-10-16
• Last updated: 2014-10-28

Locations

15 sites across 1 country: Spain